Progress in Clinical Application of Bispecific Antibodies in Colorectal Cancer Treatment

The incidence of colorectal cancer(CRC) is increasing in the decade, which has caused a serious burden for the individual and society. Although the targeted therapy and immunotherapy has significantly improved the clinical prognosis of CRC patients, the problems of drug resistance and low immune response rate hinder its further development of overall cure rate. Bispecific antibody(BsAb) as a hot field recently, and the problems of drug resistance and low immune response might be solved through the design of double targets. In this paper, several main types of BsAb used for CRC treatment at present are systematically reviewed, the different targets of BsAb and its clinical application progress in CRC treatment are discussed. Trying to provide useful reference for the subsequent research and design of BsAb for CRC treatment.